| |
|
Headlines:
|
 |
Back
to index
Docetaxel single agent
Abstract: Phase II trials of docetaxel (Taxotere) in advanced ovarian
cancer--an updated overview.
Docetaxel (Taxotere) has been studied at a dose of 100 mg/m2 i.v. as
a one hour infusion every 3 weeks, in four phase II trials in patients with
extensively pretreated ovarian cancer. A total of 340 patients were treated,
including 256 patients in two separate EORTC (European Organization for
Research and Treatment of Cancer) trials and 84 patients in two trials in
the U.S.A. All patients had received prior cisplatin or carboplatin therapy
and the treatment-free interval was less than 4 months in 155 patients.
The overall response rate using conventional UICC criteria was 30% among
315 evaluable cases (95% confidence interval: 24-36%). Among 155 patients
whose disease was most refractory (i.e. treatment-free interval was less
than 4 months), the overall response rate was 28% (95% confidence interval:
19-36%). Response duration ranged from 4 to 17 months. Grade IV neutropenia
was a common finding and fluid retention was observed. The incidence of
febrile neutropenia ranged from 8 to 44% of patients with two deaths (i.e.
0.6% of the total treated) related to neutropenic sepsis. Docetaxel and
paclitaxel (Taxol) have comparable activities in ovarian cancer. Ongoing
studies with docetaxel include its use in patients as part of first-line
therapy, as well as in patients refractory to paclitaxel. To prevent the
development of fluid retention, these now involve the routine use of steroid
prophylaxis. It is expected that docetaxel will prove to be an important
addition to the drugs available for the treatment of ovarian cancer.
References
Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of
docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. Eur
J Cancer 1997; 33:2167 - 2170.
|
|
|
|
Are you a doctor or a nurse?
Do you want to join the Doctors Lounge online medical community?
Participate in editorial activities (publish, peer review, edit) and
give a helping hand to the largest online community of patients.
Click on the link below to see the requirements:
Doctors Lounge Membership
Application |
|
| Regimen |
|
Docetaxel....... 100 mg / M2
IV (over 1 h) day 1
FREQUENCY every 21 days |
|
|
| |
|
|
| |
Summary |
|
| |
Overall Response
Rate |
|
| |
Progression
Free Survival |
|
| |
Overall Survival |
|
| |
Toxicity |
|
| |
|
|
|
|
send
to a friend
printer
friendly version
